AbbVie (NYSE: ABBV) and Repligen Corporation (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitabiliy.


AbbVie pays an annual dividend of $2.56 per share and has a dividend yield of 3.6%. Repligen Corporation does not pay a dividend. AbbVie pays out 62.9% of its earnings in the form of a dividend. Repligen Corporation has raised its dividend for 44 consecutive years.

Valuation & Earnings

This table compares AbbVie and Repligen Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
AbbVie $26.71 billion 4.23 $11.39 billion $4.07 17.44
Repligen Corporation $110.04 million 12.86 $27.41 million $0.51 81.43

AbbVie has higher revenue and earnings than Repligen Corporation. AbbVie is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AbbVie has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Repligen Corporation has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AbbVie and Repligen Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbbVie 0 7 6 1 2.57
Repligen Corporation 0 2 2 0 2.50

AbbVie presently has a consensus price target of $75.54, suggesting a potential upside of 6.41%. Repligen Corporation has a consensus price target of $41.00, suggesting a potential downside of 1.28%. Given AbbVie’s stronger consensus rating and higher probable upside, research analysts plainly believe AbbVie is more favorable than Repligen Corporation.


This table compares AbbVie and Repligen Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AbbVie 24.77% 154.76% 12.56%
Repligen Corporation 15.61% 9.90% 5.93%

Insider and Institutional Ownership

67.9% of AbbVie shares are owned by institutional investors. Comparatively, 99.0% of Repligen Corporation shares are owned by institutional investors. 0.2% of AbbVie shares are owned by company insiders. Comparatively, 1.5% of Repligen Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


AbbVie beats Repligen Corporation on 12 of the 18 factors compared between the two stocks.

AbbVie Company Profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with's FREE daily email newsletter.